OncoSec Medical Inc

OncoSec Medical Inc. is a biotechnology company headquartered in Trenton, New Jersey. The company employs 39 people and generates approximately $50 million in annual revenue. OncoSec specializes in developing innovative technologies that harness the body's immune system to combat cancer. Their primary focus is on TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12) designed for targeted and sustained delivery within tumors. This technology aims to stimulate a local and systemic anti-tumor response. OncoSec's TAVO™ has shown promising results in several clinical trials, including studies for metastatic melanoma and metastatic triple-negative breast cancer. These trials have demonstrated the potential for TAVO™ to provide effective treatment options for patients with limited or no other viable therapies. Interested parties can learn more about OncoSec Medical Inc. and their groundbreaking cancer treatments by visiting their website at oncosec.com.